October 2019

October 18, 2019

In the October Editor-in-Chief letter, Dr. Jason Gallagher writes about the role clinicians play in helping patients understand antibiotic resistance.

October 17, 2019

Rising incidence of viral and bacterial infections has accompanied the opioid crisis, but it also presents new opportunities for multidisciplinary treatment and preventive care.

October 16, 2019

When the CD4 count seems too good to be true.

October 15, 2019

By stopping unnecessary antibiotics before they start, clinicians can avoid unnecessary harm to the patient and the population.

October 14, 2019

Novel β-lactam/β-lactamase inhibitor combinations and cefiderocol may play a part in the treatment of infections caused by Stenotrophomonas maltophilia, Achromobacter xylosoxidans, and Burkholderia cepacia complex.

October 11, 2019

Patients with a new diagnosis of HIV may benefit from rapid start of ART.

October 10, 2019

The high recurrence rates of Clostridioides difficile infection highlight the need for novel agents with unique mechanisms of action for treating the infection.

October 09, 2019

Updates include novel and revised breakpoints for azithromycin, polymyxins, daptomycin, and cefiderocol.

October 08, 2019

One promising proposal to greatly increase access to DAA HCV therapy is to keep this treatment with appropriately trained PCPs, in contrast with referring patients to infectious disease, gastroenterology, or hepatology subspecialists.

October 07, 2019

Unsurprisingly, STD clinics have reported increased patient interest in PrEP; however, these clinics often face challenges in providing longitudinal patient care because of limited resources and capacity.